Article Text

Download PDFPDF
4CPS-088 Direct-acting antivirals for the treatment of hepatitis c virus infection: a real-world data analysis
  1. A Garcia Sacristan,
  2. JM Martínez-Sesmero,
  3. H Quirós Ambel,
  4. FJ Manzano Lista,
  5. A Dominguez Barahona,
  6. S Gonzalez Suarez,
  7. P Moya Gómez
  1. Hospital Virgen de la Salud, Pharmacy, Toledo, Spain


Background The use of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) patients has been a controversial issue over the past years in medicine. It has changed the HCV treatment paradigm, becoming a disease that can be cured. An extensive literature has documented the efficacy of these agents in the general population with cure rates>90%.

Purpose Evaluate DAAs real-life effectiveness and safety in mono-infected HCV patients.

Material and methods Observational, retrospective and analytical study, involving mono-infected HCV patients treated with DAAs since April 2016 in a teaching general hospital. Demographic variables: genotype(GT), liver fibrosis, treatment naïve or not, DDAs combination, treatment duration and sustained viral response at week 12 post-treatment (SVR-12) were obtained from the electronic health record. Data were collected in Excel®2010 and statistical intention to treat analysis (ITT) was performed with SPSS®v21.

Results A total of 391 patients have been treated with DDAs, 330 of whom have been followed up until week 12 post-treatment. Of these 330 patients: 43.64% (144) were females, mean age 58.62 years (min 22 – max 85); 48.79% (161) GT1a, 42.12% (139) GT1b, 0.30% (1) GT1c, 0.61% (2) GT2, 4.85% (16) GT3, 3.03% (10 )GT4, 0.30% (1) GT5; 2.73% (9) F0, 6.06% (20) F1, 29.69% (98) F2, 19.70 (65) F3, 37.58% (124) F4% and 4.24% (14) undetermined fibrosis; 24.85% (82) interferon pretreated (50 no responders – NR, 32 relapses – RR); 5.76% (19) SOF+SMV, 22.73% (75) with SOF+DCV, 40% (132) SOF/LDP, 29.39% PTV/r/OBV+DSV, 2.12% (7) ELB/GZP; 9.09% (30) were treated within 8 weeks, 5.21% (169) within 12 weeks and 39.69% (131) within 24 weeks.

IIT analysis determined that 96.97% (320) patients had RVS12: two exitus; four patients dropped out the medication: three with SOF+LDP and one with SOF+DCV. Two patients discontinued treatment because of adverse events – AE (headache and nausea); two virologic failures with PTV/r/OBV+DSV and other two relapsers: one with PTV/r/OBV+DSV and one with SOF+SMV. Therefore, 100% (seven) of patients with EBV/GZP achieved SVR-12, 96.90% (94) with PAR/OMB+DAS, 96.96% (128) with SOF+LDP, 97.33% (73) with SOF+DAC and 94.74% (one) with SOF+SMP.

Conclusion High SVR-12 rates have been achieved in real-world settings with similar data to those clinical trials. Virological failures and relapsers were due to wrong genotyped assignment. Therapeutic drop-outs were caused by specific individual factors, such as social problems and acute processes that caused DDAs discontinuation, but also two cases of AE. Even so, a new generation of DDAs leads to better tolerance. These results suggest that eradication of HCV is feasible, carrying out a good screening strategy and high treatment access.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.